New World Advisors LLC Has $364,000 Stake in Johnson & Johnson (NYSE:JNJ)

New World Advisors LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,194 shares of the company’s stock after purchasing an additional 216 shares during the quarter. New World Advisors LLC’s holdings in Johnson & Johnson were worth $364,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson during the fourth quarter worth $29,000. Conquis Financial LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $33,000. Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson during the fourth quarter worth $36,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in Johnson & Johnson during the fourth quarter worth $38,000. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on JNJ shares. The Goldman Sachs Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Wall Street Zen upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 21st. Morgan Stanley upped their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 16th. Benchmark upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 5th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $152.44 on Friday. The stock’s 50-day simple moving average is $153.75 and its 200 day simple moving average is $153.71. The stock has a market capitalization of $366.78 billion, a price-to-earnings ratio of 16.96, a price-to-earnings-growth ratio of 2.30 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.41%. Johnson & Johnson’s dividend payout ratio is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.